Core Viewpoint - Shenzhen is advancing its comprehensive reform pilot program, achieving significant economic growth and setting ambitious goals for further reform and opening up [1][2]. Economic Growth - Shenzhen's GDP increased from 2.78 trillion yuan in 2020 to 3.68 trillion yuan in 2024, with an average annual growth rate of 5.5% [1]. - The city's industrial output and added value have ranked first among national cities for three consecutive years [1]. Reform Initiatives - The issuance of the "Opinions on Deepening Reform and Innovation in Shenzhen's Comprehensive Reform Pilot" on June 10 marks a new phase for the reform pilot [1][3]. - The reform pilot has seen the implementation of 40 authorized measures and the promotion of 48 innovative initiatives nationwide [2]. Key Focus Areas - The reform emphasizes innovation in education and technology, aiming to create a globally influential industrial and technological innovation center [3]. - There is a strong focus on integrating innovation chains, industrial chains, financial chains, and talent chains to support key industries and enterprises [3]. - Expansion of cooperation with Hong Kong and Macau is prioritized, particularly in trade and personnel movement, to enhance international collaboration [3]. Healthcare and Data Innovation - At the AI Empowerment Conference for the pharmaceutical and medical device industry, Shenzhen Data Exchange introduced five medical data products to support AI companies [4]. - The exchange aims to drive reforms and innovations in the healthcare sector, contributing to the development of a globally influential digital city [4].

Group 1 - The AI-enabled Shenzhen Pharmaceutical and Medical Device Industry High-Quality Development Conference successfully took place, focusing on how data and algorithms can assist in drug and medical device research, precision medicine, and health management [1] - The conference marked the launch of the "Clinical Empowerment for Ten Million Population Scenarios" platform, establishing Shenzhen as a leader in creating an AI medical application ecosystem covering a super-large city population [1] - The platform aims to enhance the efficient collaboration of medical resources and accelerate the application of AI drug and medical device technologies from laboratories to real-life scenarios [1] Group 2 - The Shenzhen Data Exchange's establishment is a key initiative for implementing the Shenzhen Comprehensive Reform Pilot Plan (2020-2025), focusing on data empowerment for high-quality economic development [2] - The Shenzhen Data Exchange has created a full-process service system for data rights confirmation, pricing, trading, usage, and regulation, aiming to explore market-oriented data element allocation paths [2] - Five high-quality medical data products were listed at the event, focusing on public health, chronic disease management, vaccination, and treatment behaviors, providing a solid data foundation for AI drug and medical device companies [2] Group 3 - Huasheng Medical, the first certified data vendor in the medical device sector at the Shenzhen Data Exchange, has launched both data set and data tool assets, creating a complete value chain from "data raw materials" to "intelligent tools" [3] - The company aims to collaborate with China Unicom, Shenzhen Data Exchange, and hospitals to enhance hardware and data training, providing more intelligent devices [3]

Summary of Medical Data Circulation and Trading Conference Call Industry Overview - The conference call discusses the medical data industry in China, focusing on the circulation and commercialization of medical data assets, particularly in major hospitals in Beijing and other cities like Shenzhen and Shanghai [1][2]. Key Points and Arguments 1. **Expansion of Medical Data Trials**: In 2024, the Beijing Health Commission and Economic and Information Bureau will expand medical data trials to 22 major hospitals, promoting the assetization of medical data [1][2]. 2. **Challenges in Data Sharing**: Hospitals face challenges such as low levels of information technology and insufficient data demand. Solutions include improving IT infrastructure, clarifying data needs, and providing policy and financial support [1][3]. 3. **Policy as a Driving Force**: National policies are crucial for the circulation of medical data. The National Data Bureau actively promotes data sharing plans and encourages hospitals to open their data elements [1][2]. 4. **Demand for Specialized Data**: Hospitals prefer to trade representative specialized disease data, with demand typically driven by commercial value [1][4]. 5. **AI's Impact on Data Demand**: The development of AI in healthcare has significantly increased the demand for medical data, shifting focus from basic medical records to high-value data such as expert notes on complex cases [1][6]. 6. **Lack of Standard Pricing**: There is no unified pricing standard for medical data, which is usually based on asset valuation and costs associated with technical teams and data annotation [1][6]. 7. **Data Ownership Issues**: The issue of data ownership is a major barrier to commercial applications. Anonymization is key, as anonymized data can belong to hospitals, facilitating data circulation [1][12][16]. 8. **Successful Case Studies**: Successful data trading cases, such as the orthopedic data assetization by Jishuitan Hospital, demonstrate the potential for hospitals to monetize their data [2][5]. 9. **Regulatory Environment**: The regulatory environment is evolving, with Beijing providing clear guidelines for medical data transactions, encouraging innovation and pilot projects [4][21]. 10. **Collaboration Among Hospitals**: Hospitals are exploring collaborative models for data standardization and revenue sharing, which could serve as a benchmark for future projects [13][20]. Additional Important Insights - **Diverse Data Needs**: Different types of data, such as imaging and clinical data, are in demand, with top hospitals being preferred sources due to their quality and quantity of data [7][10]. - **Non-Exclusive Data Sales**: Data can be sold to multiple buyers unless there is an exclusivity agreement, which can increase the price [8]. - **Impact of Population Size**: China's large population provides a vast amount of high-quality medical data, which is advantageous for developing medical AI models [14]. - **Third-Party Collaborations**: Third-party companies can collaborate with hospitals to develop specialized AI models, provided they follow legal and compliance processes [22][23]. - **Future of Data Standardization**: Efforts are underway to standardize and connect medical data across regions, although challenges remain [11][30]. This summary encapsulates the key discussions and insights from the conference call regarding the medical data industry, highlighting the opportunities and challenges in data circulation and commercialization.